AstraZeneca Plc said on March 14 a review of safety data of people vaccinated with the company’s Covid-19 vaccine has shown no evidence of an increased risk of blood clots.
Novavax Inc.’s Covid-19 vaccine was 96 percent effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on March 11, moving it a step closer to regulatory approval.
The Covid-19 vaccine from Pfizer Inc. and BioNTech SE was able to neutralize a new variant of the coronavirus spreading rapidly in Brazil, according to a laboratory study published in the New England Journal of Medicine on March 8.
Covid-19 vaccine confidence grows as side effect worries fade
Australia, BNT162b2 (Pfizer and BioNTech), Britain, Canada, Countries, COVID-19 vaccine rollout, COVID-19 Vaccines, Denmark, France, Germany, Imperial College London’s Institute of Global Health Innovation (IGHI), Israel, Italy, Japan, Norway, Singapore, South Korea, Spain, Surveys, Sweden, The Netherlands, United KingdomConfidence in Covid-19 vaccines is growing, with people’s willingness to have the shots increasing as they are rolled out across the world and concerns about possible side effects are fading, a 14-country survey showed on March 5.
Fauci says U.S. must stick to two-shot strategy for Pfizer, Moderna Covid-19 vaccines: paper
BNT162b2 (Pfizer and BioNTech), COVID-19 shots, COVID-19 Vaccines, Covid-19 Variants, Dr. Anthony Fauci (Director), Health Officials, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Pfizer, Science, The Washington Post, U.S. government, United KingdomThe United States must stick to a two-dose strategy for the Pfizer-BioNTech and Moderna Covid-19 vaccines, top U.S. infectious disease official Anthony Fauci told the Washington Post newspaper.
Public Health England (PHE) published real-world analyses of people in the U.K. who had received the first shot of the Pfizer-BioNTech Covid-19 vaccine, with the data – which were published in The Lancet – showing that there was a decrease of about 70 percent in infections among healthcare workers after the first shot.
Drug developer Novavax Inc. completed enrolling 30,000 volunteers in a late-stage study of the company’s Covid-19 vaccine in the United States and Mexico.
The United States reported a 23% drop in new cases of Covid-19 and a 16% fall in the number of people hospitalized with the virus for the week ended Feb. 14, with both figures declining for a fifth week in a row.
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.
Almost all people previously infected with Covid-19 have high levels of antibodies for at least six months that are likely to protect them from reinfection with the disease, results of a major UK study showed.